Human medicines European public assessment report (EPAR): Onbevzi, bevacizumab, Date of authorisation: 11/01/2021, Revision: 5, Status: Withdrawn (authorisation)
Pharmacovigilance Risk Assessment Committee (PRAC): 24 - 27 November 2025, European Medicines Agency, Amsterdam, the Netherlands, from 24 November 2025 to 27 November 2025
Pharmacovigilance Risk Assessment Committee (PRAC): 27 - 30 October 2025, European Medicines Agency, Amsterdam, the Netherlands, from 27 October 2025 to 30 October 2025
Pharmacovigilance Risk Assessment Committee (PRAC): 29 September - 2 October 2025, European Medicines Agency, Amsterdam, the Netherlands, from 29 September 2025 to 2 October 2025
Pharmacovigilance Risk Assessment Committee (PRAC): 1 - 4 September 2025, European Medicines Agency, Amsterdam, the Netherlands, from 1 September 2025 to 4 September 2025
Pharmacovigilance Risk Assessment Committee (PRAC): 4 - 7 August 2025, European Medicines Agency, Amsterdam, the Netherlands, from 4 August 2025 to 7 August 2025
Pharmacovigilance Risk Assessment Committee (PRAC): 5 - 8 May 2025, European Medicines Agency, Amsterdam, the Netherlands, from 5 May 2025 to 8 May 2025
Human medicines European public assessment report (EPAR): Jylamvo, methotrexate, Date of authorisation: 29/03/2017, Revision: 15, Status: Authorised
The 9th EFIM Day was held at the Crowne Plaza Hotel on Friday, 18 October. We were delighted to host representatives from 19 EFIM national societies, fostering lively discussions and an exchange of valuable experiences.
Prof. Ricardo Gomez Huelgas, EFIM President, opened the meeting by welcoming participants and expressing gratitude for the support and contributions to EFIM’s initiatives over the past year.
Read more details of the 9th EFIM Day here:
Veterinary medicines European public assessment report (EPAR): ProteqFlu, Equine influenza vaccine (live recombinant), Revision: 14, Status: Authorised